Drugs / 2X-121
2X-121
also known as
E7449 · 9X5A2QIA7C · CS-3479 · HY-12418 · MGI25036 · PARP INHIBITOR 2X-121 · PMID27841036-COMPOUND-37 · Stenoparib · +2 more
Small molecule targets PARP1, PARP2 via inhibition
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05571969 | Mar 2023 → Feb 2024 | cancer | Allarity Therapeutics | Terminated | No outcome recorded Stop: Business |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06681220 | Feb 2026 → Dec 2029 expected | small cell lung carcinoma | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02396433 | Apr 2015 | breast cancer | The University of Texas Health Science Center at San Antonio | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT01618136 | Jan 2012 → Jul 2015 | indolent B-cell non-Hodgkin lymphoma, melanoma, ovarian carcinoma, triple-negative breast carcinoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03878849 | Apr 2019 → Mar 2027 expected | ovarian cancer | Allarity Therapeutics | Recruiting | No outcome recorded |
| Phase 2 | NCT03562832 | Jun 2018 → Apr 2024 | breast cancer | Allarity Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 14
| Date | Issuer | Release |
|---|---|---|
| 2026-04-21 | Allarity Therapeutics | Results Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer allarity.com ↗
This poster highlights clinical data demonstrating that the highest stenoparib DRP® scores are associated with enhanced overall survival in patients treated with stenoparib, reinforcing the value of DRP-based patient selection in ring-fencing those patients most likely to benefit from stenoparib. |
| 2025-09-22 | Allarity Therapeutics | Results Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months allarity.com ↗
The mOS has not been formally reached yet and now exceeds 25 months. |
| 2025-08-26 | Allarity Therapeutics | Regulatory Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer allarity.com ↗
“We are very pleased that the FDA has granted Fast Track designation to stenoparib,” said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics. |
| 2025-03-17 | Allarity Therapeutics | Results Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology allarity.com ↗
Stenoparib has shown clinical benefit in heavily pre-treated patients, including those with platinum-resistant and refractory ovarian cancer |
| 2024-11-18 | Allarity Therapeutics | Results Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements allarity.com ↗
Two patients in Allarity’s Phase 2 clinical trial of stenoparib for advanced, recurrent ovarian cancer have now been on treatment for over 14 months, a remarkable duration of benefit given the heavily pretreated status of these patients. |
| 2024-09-16 | Allarity Therapeutics | Results Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial allarity.com ↗
The trial continues to evaluate stenoparib’s safety and efficacy, showing a confirmed, complete response as well as long term disease stability for multiple patients. |
| 2024-06-25 | Allarity Therapeutics | Results Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer allarity.com ↗
Multiple patients have now exceeded 30 weeks on treatment |
| 2024-05-14 | Allarity Therapeutics | Results Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances allarity.com ↗
Our trials of stenoparib in advanced, recurrent ovarian cancer have yielded encouraging proof of concept data, which further boosted our optimism for the future of this novel PARP inhibitor. |
| 2024-05-02 | Allarity Therapeutics | Results Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer allarity.com ↗
The trial, evaluating stenoparib given twice daily, has shown clear clinical benefit, including tumor shrinkage and long-term disease stability, in heavily pre-treated ovarian cancer patients who otherwise have limited life expectancy. |
| 2023-12-05 | Allarity Therapeutics | Results Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic allarity.com ↗
Of the five evaluable patients included in the initial data analysis, one patient experienced a complete response and the other four demonstrated stable disease. |
| 2021-11-11 | Allarity Therapeutics | Results Allarity Therapeutics’ Oral PARP Inhibitor, Stenoparib, Demonstrates Pre-clinical Antiviral Activity Against Delta Variant of Coronavirus allarity.com ↗
Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced positive results from the further pre-clinical testing of the antiviral activity of its oral PARP inhibitor, stenoparib, against Coronavirus variant B.1.617.2 (delta variant). |
| 2021-08-05 | Allarity Therapeutics | Results Allarity Therapeutics’ oral PARP inhibitor, Stenoparib, demonstrates additional pre-clinical antiviral activity against new variants of Coronavirus allarity.com ↗
Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced positive results from the further pre-clinical testing of the antiviral activity of its PARP inhibitor, stenoparib, against Coronavirus variant B.1.1.7 (British variant). |
| 2018-06-01 | Allarity Therapeutics | Results MPI – Clinical data on PARP inhibitor 2X-121 and DRP response prediction validation to be presented on the world’s largest cancer congress ASCO 2018 allarity.com ↗
2X-121 is active and our DRP ® shows excellent prediction in a field with very successful competing products and a challenge to obtain precision |
| 2018-05-16 | Allarity Therapeutics | Results MPI: Medical Prognosis Institute and Oncology Venture Announces Abstracts on Three Pipeline Products Selected for 2018 ASCO Clinical Meeting allarity.com ↗
The 2X-121 DRP® successfully predicted the responders to treatment with 2X-121, irrespective of BRCA mutation status. |
All press releases naming this drug 49 releases
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2X-121 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03562832 ↗ |
| Known as | 9X5A2QIA7C | ChEMBL registry synonym — accepted as the source's own label CHEMBL3644587 ↗ |
| Known as | CS-3479 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3644587 ↗ |
| Known as | E7449 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01618136 ↗ |
| Known as | HY-12418 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3644587 ↗ |
| Known as | MGI25036 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3644587 ↗ |
| Known as | PARP INHIBITOR 2X-121 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3644587 ↗ |
| Known as | PMID27841036-COMPOUND-37 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3644587 ↗ |
| Known as | Stenoparib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06681220 ↗ |
| Known as | STENOPARIB (E7449) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3644587 ↗ |
| Known as | UNII-9X5A2QIA7C | ChEMBL registry synonym — accepted as the source's own label CHEMBL3644587 ↗ |
| Action | Inhibit | “E7449, a novel PARP 1/2 and tankyrase 1/2 inhibitor.” PMID 32523090 ↗ Jun 20202“Poly [ADP-ribose] polymerase 2 inhibitor” CHEMBL3644587 ↗ “Poly [ADP-ribose] polymerase-1 inhibitor” CHEMBL3644587 ↗ |
| Modality | Small molecule | “2X-121 is a small molecule targeted inhibitor” NCT03562832 ↗ |
| Route | Oral | “E7449 will be administered as single agent orally, once daily (QD) continuously in 28-day cycles” NCT01618136 ↗ |
| Target | PARP1 | “Poly [ADP-ribose] polymerase-1 inhibitor” CHEMBL3644587 ↗ |
| Target | PARP2 | “Poly [ADP-ribose] polymerase 2 inhibitor” CHEMBL3644587 ↗ |